Loading
A phase 1/2 trial of Selinexor, Dexamethasone, Lenalidomide in multiple myeloma, run by Karyopharm Therapeutics Inc, now recruiting.
Selinexor and Backbone Treatments of Multiple Myeloma Patients is a phase 1/2 interventional study registered as NCT02343042 by Karyopharm Therapeutics Inc, with 300 participants planned, started 2015-10 and due to reach its primary completion in 2027-04. Interventions recorded: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Karyopharm Therapeutics, Selinexor, Bortezomib, Dexamethasone.
Shares Daratumumab, Bortezomib, Lenalidomide, Dexamethasone.
Shares Karyopharm Therapeutics, Selinexor, Small-molecule kinase inhibitors.
Shares Pomalidomide, Daratumumab, Lenalidomide, Dexamethasone.
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
Shares Selinexor, Daratumumab, Lenalidomide, Multiple myeloma.
Shares Selinexor, Pomalidomide, Bortezomib, Dexamethasone.
Shares Pomalidomide, Bortezomib, Lenalidomide, Dexamethasone.